As of 2025-07-04, the EV/EBITDA ratio of Arrayit Corp (ARYC) is -0.16. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ARYC's latest enterprise value is 1 mil USD. ARYC's TTM EBITDA according to its financial statements is -6 mil USD. Dividing these 2 quantities gives us the above ARYC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
Range | Selected | |
Trailing EV/EBITDA multiples | 13.5x - 16.0x | 16x |
Forward EV/EBITDA multiples | 17.3x - 22.6x | 20.5x |
Fair Price | (0.13) - (0.12) | (0.13) |
Upside | -13192168.8% - -12238077.5% | -13184596.7% |
(USD in millions except Fair Price) | |||
Trailing | Forward | ||
Market Cap (USD mil) | EV/EBITDA | EV/EBITDA | |
Arrayit Corp | 0 | N/A | N/A |
Bruker Corp | 6,432 | 14.4x | 18.1x |
Harvard Bioscience Inc | 20 | 7.8x | 7.8x |
Illumina Inc | 15,957 | 16x | 16x |
International Isotopes Inc | 41 | 68.8x | 70x |
Luminex Corp | 1,750 | 20.3x | 25.8x |
Pacific Biosciences of California Inc | 480 | 3.6x | 3.6x |
PerkinElmer Inc | 14,568 | 12.1x | 20.5x |
Qiagen NV | 10,469 | 16x | 35x |
Bio-Techne Corp | 8,331 | 26.2x | 29.7x |
Industry median | 16x | 20.5x | |
(*) EBITDA | -6 | -6 | |
Enterprise value | (91) | (117) | |
(-) Net debt | 1 | 1 | |
Equity value | -92 | -118 | |
(/) Outstanding shares | 755 | 755 | |
Fair price | -0 | -0 | |